Sign inSubscribe

target directory

azd8233 subcutaneous injection placebo clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT04155645
Source recordAI-normalized

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Multiple Ascending Subcutaneous Dose Administration in Subjects With Dyslipidemia With or Without Type 2 Diabetes

This is a Phase I study to assess the safety, tolerability and pharmacokinetics (PK), and pharmacodynamics (PD) of AZD8233, following subcutaneous (SC) administration of multiple ascending doses (MAD) of AZD8233 in subjects with confirmed dyslipidemia with or without type 2 diabetes.

AI analysis

Indication: Dyslipidemia

Modality: small molecule

Target: AZD8233 subcutaneous injection, Placebo

Sponsor: AstraZeneca

Source URL: ClinicalTrials.gov

Source updated: Jun 30, 2021

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: AZD8233 subcutaneous injection, Placebo

View original source fields

Condition raw: Dyslipidemia

Condition normalized: Dyslipidemia

Modality raw: small molecule

Modality normalized: small molecule

Target raw: AZD8233 subcutaneous injection, Placebo

Target normalized: AZD8233 subcutaneous injection, Placebo

Open report